Lymphedema therapy in head & neck cancer with carotid stenosis: a systematic review and care pathway.

Oral OncolJun 30, 2026 (epub)
Clinical ResearchOncology (Medical)CardiologyPhysical Medicine & Rehabilitation

Aaron Chang, Douglas Jacoby, Alexander Lin et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review aimed to develop a clinical care pathway for managing lymphedema in head and neck cancer survivors at risk for carotid atherosclerosis. Despite identifying 85 articles, none provided direct guidance on this overlap. The working group proposed a preliminary pathway based on available evidence and expert consensus.

Key findings

  • No articles directly addressed lymphedema management in irradiated head and neck cancer survivors with carotid atherosclerosis.
  • A preliminary clinical care pathway was developed based on limited evidence and expert consensus.
  • The review highlights a significant gap in clinical practice guidelines for this patient population.

Why it matters

The coexistence of lymphedema and carotid artery atherosclerosis in head and neck cancer survivors complicates management. Establishing a care pathway can help clinicians navigate these challenges and improve patient outcomes.

Source

PubMed · PMID 42378749

Published in Oral Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.